Mabwell

Mabwell (Shanghai) Bioscience is a values-based, R&D-driven biopharmaceutical company established in 2017. It dedicates its extensive research efforts to five critical therapeutic areas: immunology, oncology, metabolic diseases, ophthalmology, and infectious diseases. The company has cultivated a robust R&D infrastructure, featuring advanced platforms for hybridoma antibody discovery, B cell screening, ADC drug development, PEGylation technology, and bispecific antibody development. This integrated approach enables Mabwell to pursue innovation across the entire drug development lifecycle.

The company's world-class R&D engine is powered by a thriving team of biopharmaceutical scientists. These experts span drug discovery, development, manufacturing, and commercialization, ensuring a comprehensive approach to bringing novel therapies to market. Mabwell's commitment to scientific excellence is evident in its state-of-the-art facilities and its focus on creating high-throughput screening capabilities for new molecular discovery. Meet Mabwell (Shanghai) Bioscience's team to understand the expertise driving these advancements.

Operating with 500 - 1,000 employees, Mabwell (Shanghai) Bioscience has demonstrated significant growth and market presence. The company has secured substantial funding, including a Series A round of $278 million in April 2020 and a subsequent stock issuance in January 2022. Its revenue reached $34.5M, underscoring its operational capacity and market traction. Mabwell's strategic investments and revenue generation highlight its position as a key player in the biopharmaceutical sector. Explore financial highlights for detailed metrics on its financial performance and investment rounds.